Yves Decadt appointed CEO of Poxel

Poxel has announced the appointment of Yves Decadt as Chief Executive Officer, effective June 10. He succeeds Nicolas Trouche, whose mandate was specifically designed to lead the company through the restructuring period initiated in August 2025. This previously agreed transition is proceeding according to the established schedule.

A member of the Board of Directors since October 21, 2025, Yves Decadt 'possesses all the necessary experience to drive the operational implementation of the Continuation Plan approved by the Lyon Economic Activities Court in January 2026', according to the biopharmaceutical company.

With over 25 years of international experience in the pharmaceutical industry, Yves Decadt spent nearly 20 years at Johnson & Johnson within the international business development department, where he was responsible for licensing and agreement negotiations, with particular expertise in the Asian region.

His short- and medium-term priorities will be to accelerate partnership discussions for the commercialization of Imeglimin outside Japan, with a specific focus on China and Asian markets, and to unlock the value of PXL065 for the treatment of hypertrophic cardiomyopathy (HCM) and metabolic dysfunction-associated steatohepatitis (MASH).